Judith Robinson is national practice head of our intellectual property practice in Canada and practises as a barrister, solicitor and trade-mark agent in all areas of intellectual property law, with a particular emphasis on intellectual property litigation before the courts and alternative dispute resolution. She is also active in various administrative law matters that arise in relation to intellectual property rights, including the representation of clients before administrative tribunals and judicial review applications to the Federal Court.
As regards trial work, Ms. Robinson was lead counsel to Bell Helicopter Textron Canada Limited in a patent infringement and validity action (2012 FC 113). She led a team to a successful judgment in 2008 that the Servier perindopril patent was valid and infringed, defeating a counterclaim that asserted anti-competitive practices. Prior to that, she was counsel to Merck in obtaining a judgment of infringement and validity of Merck’s patent for lisinopril. She has particular experience in expedited trial procedure, including her role as counsel on a “test case” fast-track patent action before the Federal Court. Ms. Robinson is also involved in the damages assessment phase of intellectual property litigation.
In the pharmaceutical sector, Ms. Robinson has been active in litigation and strategic work related to the Patented Medicines (Notice of Compliance) Regulations since the introduction of this regime in 1993, as well as the subsequent data protection legislation. She also counsels clients on various regulatory matters.
The solicitor work in which she is involved includes freedom to operate, validity and infringement opinions across a variety of industries, as well as commercial agreements.
Ms. Robinson previously served as chair of the Montréal intellectual property group and then as Quebec regional chair of our intellectual property practice.
Year of call
Year of registration
Canada (trade-marks) 1992
LL.B./B.C.L., McGill University, 1990
B.A., Psychology - Neuropsychology and Neurophysiology, McGill University, 1985
Ms. Robinson is regularly asked to give presentations on intellectual property law, including the following:
- “Innovation: The Importance of Intellectual Property Protection,” The International Economic Forum of the Americas, Conference of Montreal, Montreal, June 12, 2013.
- “L’éthique dans la pratique du droit,” Les femmes en droit - La pratique du droit dans le contexte actuel, Montreal, December 2, 2011.
- “From Hair Tonic to Medicines and Beyond: A View of the Federal Courts and Intellectual Property,” Federal Courts Education Seminar, Ottawa, October 27-28, 2011.
- “Utility, Sound Prediction and Selection Patents - Clarifying Canadian standards and their impact on patent drafting, prosecution and litigation,” 9th Annual Forum on Pharma Patents, The Canadian Institute, Toronto, November 5, 2010.
- “Conflagration of Sufficiency of Disclosure and Utility,” IPIC 84th Annual Meeting, Fairmont Le Château Frontenac, Quebec City, October 15, 2010.
- “Interaction avec la Loi sur la concurrence; détermination de l’invention; la prédiction valable,” Quebec Bar Continuing Education, Hôtel InterContinental, Montreal, November 13, 2009.
- “Best Practices at Trial,” Federal Court Annual Seminar, Montreal, October 7, 2009.
- “2009 Advocacy before the Federal Court in Intellectual Property Matters CLE - To Appeal or Not To Appeal,” Hilton Lac-Leamy, Gatineau, QC, April 30, 2009.
- “Patent Infringement Cases - Trials and Tribulations,” Toronto Intellectual Property Group, King Edward Hotel, Toronto, November 5, 2008.
- “Patent Opinions and Litigation - Part 2: In the Thick of the Action,” IPIC 82nd Annual Meeting, Four Seasons Hotel, Toronto, October 16, 2008.
Selected client work
- Bell Helicopter Textron Canada Limited
- E.I. du Pont de Nemours and Company
- GlaxoSmithKline Inc.
- Merck Canada Inc.
- Merck Sharp & Dohme Corp.
- Pfizer Canada Inc.
- Pfizer Inc.
- Sanofi-aventis Canada Inc.
- Servier Canada Inc.
Rankings and recognitions
- Best Lawyers in Canada (2010-2017): Biotechnology Law; Intellectual Property Law
- Chambers Canada (2016-2017): Intellectual Property: Litigation
- The Legal 500, Canada (2016): Labour and Employment (Canada)
- IAM Patent 1000: Litigation (2016)
- Canadian Legal Lexpert Directory (2012-2016): recommended in Biotechnology; Intellectual Property; Litigation – Intellectual Property
- Chambers Global: Canada (2006-2016): Intellectual Property: Litigation
- Best Lawyers in Canada – Lawyer of the Year (2014): Biotechnology Law, Montreal
- Canadian Legal Lexpert Directory (2012): Leading US/Canada Cross-Border Litigation Lawyer, Intellectual Property
- Benchmark Canada (2012-2013): recognized as a local litigation star in Quebec
- Lexpert® Guide to the Leading US/Canada Cross-border Litigation Lawyers in Canada (2012): Litigation – Intellectual Property
- IAM Patent 1000: World’s Leading Patent Practitioners (2012)
- The International Who’s Who of Life Sciences Lawyers (2012-2013)
- IAM Patent Litigation 250: The World’s Leading Patent Litigators (2011)
- IAM Life Sciences 250: The World’s Leading Life Sciences Patent Litigators (2011)
- The International Who’s Who of Patents Lawyers (2011-2013)
- The Legal Media Group Guide to the World's Leading Patent Law Practitioners
- PLC Which Lawyer? (2010-2011): Life Sciences: Patent Litigation; Intellectual Property: Patent Litigation
- European Counsel Life Sciences Industry Report
Memberships and activities
- Fellow of the Intellectual Property Institute of Canada
- Intellectual Property Owners Association
- Licensing Executives Society
- Canadian Bar Association
The Federal Court of Appeal upheld findings of the Federal Court declaring the asserted claims of Canadian Patent No. 1,292,693 to be valid and infringed by Apotex’s manufacture, sale, and promotion of Apo-Omeprazole capsules, a generic version of AstraZeneca’s LOSEC®, but allowed Apotex’s appeal in respect of the appropriate limitation period for infringing activities..
January 18, 2017
Janssen filed an application for leave to appeal with the Supreme Court of Canada with respect to the Federal Court of Appeal decision addressing a generic manufacturer’s ability to obtain a notice of compliance by way of cross-referenced drug submission. .
December 21, 2016
Norton Rose Fulbright Canada was honoured with two awards at the fourth annual LMG Life Sciences Awards ceremony held on September 14 in New York City..
September 23, 2016
Norton Rose Fulbright is pleased to announce that Judith Robinson has been recognized a Women's Executive Network (WXN) 2015 Canada's Most Powerful Women.
December 01, 2015